LMR Partners’s GenMark Diagnostics, Inc GNMK Stock Holding History

LMR Partners’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-34,655	Closed	-$410K	–	622
2017 Q2	$410K	Buy	+34,655	New	+$443K	0.03%	429

Other funds holding GNMK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

LMR Partners's GNMK Position: Q3 2017 in Review

LMR Partners sold out of GenMark Diagnostics, Inc (GNMK) in Q3 2017, closing a stake of 34,655 shares — an estimated $410K sold.

LMR Partners first reported a position in GNMK in Q2 2017 and held it in 1 quarter. The position peaked at $410K in Q2 2017. 96 funds tracked by Wall St. Rank hold GNMK as of Q3 2017.

LMR Partners reported no remaining GenMark Diagnostics, Inc position as of Q3 2017 after selling out during the quarter.
LMR Partners sold 34,655 GenMark Diagnostics, Inc shares in Q3 2017, an estimated $410K.
LMR Partners first reported a position in GenMark Diagnostics, Inc in Q2 2017 and held it in 1 quarter.
LMR Partners's GenMark Diagnostics, Inc position peaked at $410K in Q2 2017.
96 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q3 2017.

Based on LMR Partners's 13F filing for Q3 2017, filed 9 Nov 2017.